Introduction
Opiates are among the most largely used addictive drugs. Abused opiates primarily interact with opioid receptors in the central μ nervous system and induce long-term behavioral and cellular alterations. A current challenge in opiate addiction is to understand the molecular alterations underlying the adaptative changes observed. The structure of different classes of opioid receptors, the gene encoding opioid receptors, and the signal transduction pathways triggered by opioids have been investigated extensively on neuronal cells in the last fourth decades. Chronic morphine is associated with differential gene expression in several brain structures ( ; Ammon , 2003 et al. ; ; ) . Although some of the modifications observed in rodent Beitner-Johnson , 1992 et al. Marie-Claire , 2004 et al. McClung , 2005 models of addiction could be found postmortem in the brain of opiate addicts ( , ; ), it is Ferrer-Alcon , 2000 et al.
2004 Albertson , 2006 et al. difficult to extrapolate all the results obtained from the animal brain to the patients.
Interestingly, in the case of several psychological and neurologic troubles including bipolar disorder, schizophrenia and Parkinson disease, a correlation in gene expression modulation between blood cells and brain has been recently demonstrated ( ; Bowden , 2006 et al. ) . These results suggest that studies of the transcription level of certain genes in blood cells may give insights into their Du , 2006 et al. modulation in the brain. Moreover, in the case of major depressive disorder studies of gene expression modulations showed that peripheral leucocytes exhibit unique changes in the mRNA levels of several genes that are receptive to antidepressant treatment (Iga et al 2008) .
Therefore, study of gene expression in peripheral blood mononuclear cells (PBMC) may be useful for a better understanding of brain and neurological disease related pathways, and monitoring of therapeutic responses.
On immune cells, opioid receptors with similar pharmacological and biochemical characteristics to neuronal cells have been reported ( ; ; ; ; ; ; ; Bidlack, 2000 Gaveriaux et al., 1995 McCarthy et al., 2001 Sharp et al., 1998 Sharp, 2006 Suzuki et al., 2001a Suzuki et al., 2001b  ). Moreover, morphine has been shown to interfere with lymphocytic cells functions following Suzuki et al., 2000 Wick et al., 1996 binding to these receptors ( ; ) . Chronic morphine treatment has been shown to alter a number of immune Rahim , 2002 et al. Roy , 2004 parameters including phagocytosis ( ), antibody response in mice ( ) and cytokine Hilburger, 1998 Rahim , 2002 et al. production in human and mice peripheral blood mononuclear cells (PBMCs) ( ; ). Moreover, Pacifici , 2000 et al. Peterson , 1989 et al. morphine withdrawal has been shown to alter immune response in mice ( ; ). Gaveriaux-Ruff et Belcheva , 2002 et al. Hilburger , 1997 al showed morphine immunosuppressive effects during an escalating dose protocol in mice and these effects were abolished in mu-receptor knockout animals ( ). Gaveriaux-Ruff , 1998 et al. In order to facilitate the interplay between morphine-treated rat models and opiate-dependent patients we chose to work on an easily accessible tissue: PBMCs. To evaluate whether transcriptional profiling of PBMC could serve to identify genes regulated by morphine rats were chronically treated with morphine during five days, and the behavioral signs of spontaneous withdrawal were observed at different times after the last injection to select the time point at which the animals displayed the minimum withdrawal signs for subsequent analyses.
High-density oligonucleotide arrays were used to assess global differential gene expression in the PBMCs. The changes in gene expression were also investigated for several transcripts by quantitative PCR 12h and 36h after the last injection when spontaneous withdrawal signs were minimum and maximum respectively. The regulations of the selected genes were also studied 4h before the last injection in order to estimate the influence of the withdrawal on the observed effects. The results showed that chronic morphine regulates gene expression in PBMCs and interestingly among these genes several have previously been found modulated by morphine treatment in rat brain.
Materials and Methods

Animals and drugs
Male Sprague-Dawley rats (Janvier, Le Genest-Saint-Isle, France) weighing 180 250 g at the beginning of the experiments were -housed four per cage. Animals were maintained under standard laboratory conditions (21 1 C, 55 60 relative humidity, 12h light/dark ±°-% cycle, food and water ) for 3 to 5 days before the beginning of the experiments. Care and treatments of animals conformed to the ad libitum ethical standards and guidelines promulgated by the European Communities Council Directive (86/609/EEC). All efforts were made to minimize animal suffering and to use only the number of animals necessary to produce reliable scientific data. Morphine chlorhydrate (Francopia, France) was dissolved in saline (0.9 NaCl). Morphine and saline solutions (0.1mL per 100 g of body weight) were injected % intraperitoneally.
Animal Treatments
Dependence was induced in rats by repeated intraperitoneal injections of morphine twice daily at 08.00 AM and 19.00 PM. Morphine doses were progressively increased from 10 to 40 mg kg injection: first day 2 10 mg kg , second day 2 20 mg kg , third day 2 30 mg
kg , fourth and fifth days 2 40 mg kg . Control group was treated with saline following the same procedure.
Behavioral studies
Spontaneous withdrawal syndromes were observed for 15 min in circular plexiglass observation boxes (30 cm wide; 40 cm high) 12h, 18h and 36h after the last morphine injection. Two classes of withdrawal signs were measured: counted signs and observed signs. The number of bouts of teeth chattering, wet dog shakes, mastication and tremor were counted and the sum is a score for each counted signs.
Ptosis, defecation, abnormal posture were observed over periods of 3 min, with one point being given for the presence of each sign during each period. The number of periods showing the sign was then counted (maximum score 5). Global withdrawal score was calculated as the sum of scores for all signs. Body weight was measured during the treatment and before observation period.
PBMC isolation and RNA extraction
PBMC isolation was carried out at 3 time-points: 4h before the last injection, 12h and 36h after the last injection on three independent animal groups. Animals were anaesthetized using pentobarbital (100 mg kg ) at the mentioned time points and blood was collected by 1 − intracardiac ponction (8 10 mL per animal). Rat PBMCs were isolated from whole blood by density gradient centrifugation on individually isolated from one animal whole blood. Quantification of total RNA was assessed by spectrophotometry using a Nanodrop ® instrument (Nyxor, France).
Microarray target preparation and Affymetrix hybridization
The quality of the RNA samples was determined by electrophoresis using RNA labs chips (Agilent hybridizations with morphine treatment and the five controls generated a change of P-value. The average percentage of probe sets that were called as present was 60.7 among the different hybridizations except for one of the morphine array (53.5 ), this array was then % % excluded from the subsequent study. Multiple comparisons of four morphine-treated against five control chips were therefore performed.
To identify potentially regulated transcripts we chose a cut-off of 50 fold change (treated vs.Control Assay Signal Ratio) and p<0.05.
%
Results are displayed as mean of fold induction and/or reduction. The selected transcripts after the Dchip analysis were characterized using Multiple test correction to account for the multiple hypothesis tested (one for each GO term) was applied (FDR adjusted test). in, and reverse transcriptase was inactivated by heating at 99 C for 5 min. PCR primers were chosen with the assistance of Oligo 6.42°s
Reverse transcription and
oftware (MedProbe, Norway). The primer nucleotide sequences used in this study are listed in . Fluorescent PCR analysis was Table I performed using a LightCycler instrument (Roche Diagnostics, France). The cDNAs were diluted 40-fold and 5 L were added to the 
Statistical analysis
All series of data were analyzed with GraphPad Prism 4.0 software. For behavioral experiment, three independent experiments were ® performed, 15 morphine-treated rats and 15 control rats were compared at each time-point. Data were analyzed by two-way ANOVA with
Bonferonni post-test. For body weight study three independent experiments were performed, 28 treated and placebo rats were compared at each time-point. Data were analyzed by two-way repeated measures ANOVA with Bonferonni post-test. For real-time quantitative
RT-PCR results, three additional experiments at 4h, 12h and 36h were carried out and the RNAs from 12 14 morphine-treated rats and
10 12 control rats were compared. Data were analyzed using Student s test between groups at each time point. Differences with <0.05
p between experimental groups at each point were considered statistically significant.
Results
Behavioral experiment
Physical dependence was induced in male Sprague-Dawley rats by repeated i.p injections of morphine twice daily and the withdrawal signs were monitored in order to determine the time points for the transcriptional studies. The weight gain was monitored every 12h throughout morphine treatment and withdrawal, as shown on . A significant increase of 18 was observed in control rats and the figure 1a % weight of rats treated with morphine increased by 13 during the five days of morphine treatment. This difference was not statistically % significant. The weight of the control group continued to increase during 4 days after the last injection of saline; while morphine withdrawal induced a significant reduction on weight gain in rats treated with the alkaloid. A maximum difference was observed in body weights of control versus morphine-treated rats 36h after the last injection (p<0.001) (
). Figure 1a 4 12
Morphine-withdrawn animals showed behavioral signs of opiate withdrawal, including wet dog shakes, teeth chattering, diarrhea, mastication, abnormal posture and ptosis. The calculated global withdrawal scores are presented in . Withdrawal signs were figure 1b observed at 12h, 18h and 36h after the last injection and global withdrawal scores of morphine-treated animals were significant (p<0.001) at each time-point. Twelve hours after the last morphine injection, all the withdrawal signs were already present but the global withdrawal score was less important than those calculated at 18h and 36h after the last injection. The 12h and 36h time points displaying the minimum and maximum withdrawal scores were therefore selected for the subsequent studies.
Regulation of gene expression in the PBMCs
The Affymetrix GeneChip Rat Genome RAE 230 2.0 was used to identify genes differentially regulated in the PBMCs of rats at ® + 12h after the last morphine injection. To obtain a set of differentially expressed genes and global gene expression profiling, we used a combinaison of value (P<0.05) and fold change value (>1.5 or <0.66). Comparison of chronic morphine with control condition revealed P-812 (596 up-regulated and 215 down-regulated) differentially expressed (50 fold or more) gene transcripts in PBMCs of treated rats. Of % the 812 significantly modulated candidates, only 394 were annotated and represented 276 distinct genes, whereas the others (51.5 ) were % transcripted loci with various levels of matches to known genes. A selective list of the genes modulated in this study is presented in Table   . We used NetAffix Analysis Center and FatiGO to identify the signalling pathways and genes families regulated by chronic II ™ + morphine ( ). The results revealed several genes families that have been previously described as modulated by chronic morphine in Figure 2 the brain. We found that 7 of the 276 annoted genes regulated belong to the G-protein coupled receptor protein signalling pathway, these 5-hydroxytryptamine receptors 6, 7 and 2a (Htr6, Htr7 and Htr2a), and calcium channels were also identified.
Validation of differentially regulated genes by quantitative RT-PCR at 12h
In order to validate the regulation of 24 selected genes we performed quantitative real-time RT-PCR on samples collected at the same time-point (12h) as for the array analysis (minimum withdrawal). We chose genes of the G protein pathway (Gprk5, Gng11), genes of the Mapk pathway (similar to mitogen-activated protein kinase kinase kinase kinase 5 isoform 2), mitogen-activated protein kinase 7 (Mapk7)
and genes known to be modulated in the brain by morphine treatment (Adcy5, Adenosine kinase, Htr2a). Since morphine promotes cells apoptosis, we also chose to confirm the regulation of genes implicated in this process such as Bmf, Nckap1, Timp3, and also genes implicated in cell adhesion such as Integrin beta 1 (Itgb1) and integrin alpha 6 (Itga6). Out of the 18 tested genes 12 were validated by Q-RT-PCR ( ). Furthermore, the fold-changes obtained were similar to those calculated in the array experiments ( and Table III  Table II ). We also tested 6 genes that belong to the tested families and almost fulfill the criteria detailed in the material and methods table III section: regulator of G-protein signalling 10 (Rgs10) (1.46), membrane interacting protein of Rgs16 (Mir16) (1.39), mitogen-activated protein kinase 8 interacting protein 3 (Mapk8ip3) (1,35), adaptor-related protein complex 1, sigma 1 subunit (Ap1s1) (1.36), calpain 2 (Capn2) (1.4), RAS, guanyl releasing protein 2 (Rasgrp2) (1.22). We found that the regulations of Rgs10, Mir16, Capn2, Rasgrp2, were verified by quantitative real-time RT-PCR at 12h ( ). Table III
Regulation of differentially regulated genes by quantitative RT-PCR at 36h
In order to compare the expression levels at the minimum and maximum withdrawal scores in our model, we carried out an additional independent experiment at 36h to analyze the differential expression levels between morphine-treated and control rats of 18 genes confirmed or not at 12h. Four groups of genes could be distinguished according to their pattern of regulation at 12h and 36h. Four genes + + (Adcy5, Mir 16, Camk4, and Anxa3) were significantly up-regulated at 12h but significantly down-regulated at 36h. A group with Itga6 and Rasgrp2 showed a sustained up-regulation at 12h and 36h. A group with Adk, Nckap1, Gng11, Gprk5, Rgs10, Capn2, Fgl2, Sod2, Timp3, Ap1s1, and Itgb1 showed a significant up-regulation at 12h but no modulation at 36h. And a fourth group composed of Mapk8ip3 and Htr2A was not significantly modulated at 12h but significantly regulated at 36h.
Regulation of the validated genes during chronic morphine treatment
In order to know how the validated genes were being expressed before the onset of the withdrawal process, quantitative real time PCR was performed on PBMCs of rat sacrificed on day 5. For all the tested genes the regulations observed 4h before the last morphine injection confirmed those obtained 12 hours after the last morphine injection ( ). Furthermore, the fold changes observed at 4h were very Table III − similar to those obtained at 12h. In addition no significant regulation was found at 4h for the 7 genes that were not modulated at 12H.
Discussion
The aim of this study was to identify differentially expressed genes in blood cells of morphine-dependent rats in spontaneous withdrawal situation. The large majority of studies carried out to date have used opioid receptor antagonist-precipitated withdrawal syndrome. However, this experimental approach greatly differs from the clinical setting where the opiate withdrawal syndrome occurs as a result of drug intake cessation. To better mimic these conditions, spontaneous withdrawal was evaluated. We observed classical signs used in behavioral studies and found low levels of withdrawal scores. Indeed spontaneous withdrawal induces milder behavioral modulation than the naloxone-precipitated one. As expected, the severity of opiate withdrawal varied as a function of the time interval between the last morphine administration and testing. In order to study the modifications in gene expressions in morphine-dependent rats and to minimize the transcriptional effects of withdrawal, the 12h time point was selected for microarray analysis. At this time point, withdrawal + symptoms and loss of weight were at their minimum. At 36h, the withdrawal signs were maximum, and this time point was therefore selected for comparison with the 12h results. An additional time point (4h before the last injection) was chosen in order to assess the modulation of the selected candidate genes before the beginning of the withdrawal process.
Several studies have demonstrated characteristic blood genomic profiles for different brain disorders and neurologic diseases (Du et case of migraine suffering patients differential gene expression modulations were found in platelets as compared to control patients ( ). Tang and coworkers also found a specific gene expression pattern in PBMCs from Tourette syndrome patients ( Hershey , 2004 et al. Tang ) . 
In addition morphine has been shown to modulate immune responses (
). Eisenstein and Hilburger, 1998 Interestingly, among the genes found regulated in PBMCs several have been previously reported to be involved in responses to morphine in different brain regions. The two major transcription pathways (Mapk and G protein coupled receptor) reported to be regulated by morphine treatment in brain ( ; ; ) were also found regulated in PBMCs. Asensio et al., 2006 Fan et al., 2002 Traynor and Neubig, 2005 Opioid receptor activations lead to physiological responses via coupling to inhibitory guanine nucleotide-binding regulatory protein (Gold ) , modulating several effectors, such as adenylyl cyclases, and voltage-gated Ca channels. In the present study, modulations , 2003 et al.
2+
of genes belonging to two major components of the development of opiate addiction were found in the PBMCs: the G-protein coupled receptor signalling (Gprk5, gng11, Rgs 10, Mir 16) and the cAMP signalling (Adcy5) pathways. Adcy5 has been shown to play an important role for the development of morphine behavioral effects ( ). Nestler et al have shown that decreased activation of Kim , 2006 et al. ERK1/2 might be relevant in modulating long lasting forms of synaptic plasticity in opiate addiction ( ). In the present study Nestler, 2001 we observed an increase in the expression of several mitogen-activated protein kinases (Mapk7, similar to Mapkkkk5). ). In this study we found that morphine treatment Berg , 2007 et al. upregulated two integrins genes (Itgb1 and Itga6) in rat PBMCs. Moreover, the severity of the withdrawal symptoms did not affect the expression of these two genes. Interestingly, Itgb1 has been recently shown to regulate opioid receptor signalling in sensory neurons (Berg ) . , 2007 et al.
In conclusion, our data show that chronic morphine treatment induces transcriptional modifications in PBMCs that evolve with the withdrawal state of the animals. This suggests that PBMC gene expression patterns could be indicative of the disease stage. For some of the modulated genes the PBMC regulations confirmed previously reported brain modulations. In order to better characterize the correlations suggested here, a study of the modulation of the differentially regulated genes obtained in PBMCs, in brain structures involved 6 12 in addiction, is currently carried out. This approach could help to identify important diagnostic/prognostic markers as well as potential therapeutic targets and mechanistic pathways.
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